首頁 > 市場調查報告書 > 製藥

疫苗感染疾病

市場調查報告書

商品編碼

1890959

Gardasil市場按疫苗類型、疾病預防適應症、接種方案、性別、年齡層、最終用戶、分銷管道和地區分類

Gardasil Market, By Vaccine Type, By Disease Prevention Indication, By Dosage Schedule, By Gender, By Age Group, By End User, By Distribution Channel, By Geography

出版日期: 2025年11月21日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2025 年Gardasil市場規模為 51.4 億美元，預計到 2032 年將達到 111.5 億美元，2025 年至 2032 年的複合年成長率為 11.7%。

報告內容		報告詳情
基準年：	2024	2025年市場規模：	51.4億美元
歷史數據時期：	2020-2024	預測期：	2025-2032
預測期間（2025-2032年）：	11.70%	2032 年的預測值：	111.5億美元

全球Gardasil市場是預防保健和疫苗行業的重要組成部分，專注於透過接種疫苗來預防人類乳突病毒 (HPV) 感染。Gardasil疫苗由默克公司研發，可預防導致子宮頸癌、生殖器疣和其他 HPV 相關惡性腫瘤的主要原因—特定 HPV 病毒株。與最初針對 HPV 6、11、16 和 18 型的四價疫苗（Gardasil4）相比，目前的九價疫苗（Gardasil9）顯著擴大了對九種 HPV 株的保護範圍。

該市場涉及眾多相關人員，包括製藥企業、醫療服務提供者、政府衛生機構以及各個年齡層的終端用戶。世界衛生組織 (WHO) 和美國疾病管制與預防中心 (CDC) 等國際衛生組織已將人類乳突病毒(HPV)疫苗推薦為一項重要的公共衛生措施，推動了其在已開發市場和新興市場的廣泛應用。市場動態受到多種因素的影響，例如人們對 HPV 相關疾病的認知不斷提高、疫苗接種計劃的擴展、核准用於更廣泛的年齡層和性別群體，以及對全球醫療基礎設施投資的增加，這些因素共同作用，使Gardasil成為綜合癌症預防戰略的關鍵組成部分。

市場動態

全球Gardasil市場的主要驅動力是人們對HPV相關癌症的認知不斷提高，以及對疫苗接種在減輕疾病負擔方面重要性的認知不斷增強，尤其是在預防子宮頸癌（全球女性第四大常見癌症）方面的有效性。已開發國家政府主導的計劃和國家免疫規劃顯著加快了市場滲透，許多國家已將人類乳突病毒(HPV)疫苗納入青少年常規免疫接種計劃。目標人口從最初的女性群體擴大到男性群體，顯著擴大了潛在市場，因為衛生部門認知到性別中立的疫苗接種策略對於實現群體免疫和降低HPV感染率的重要性。疫苗製劑的技術進步，特別是從四價疫苗到九價Gardasil的過渡，擴大了保護範圍並提升了其市場地位。

然而，市場仍面臨諸多限制因素。疫苗價格高昂限制了價格敏感地區的疫苗取得，文化和宗教障礙也影響疫苗接種的接受度，尤其是在性行為感染傳染病被視為禁忌的保守社會。複雜的供應鏈和冷藏保管要求也帶來了額外的挑戰，尤其是在醫療基礎設施不足的開發中國家。疫苗冷藏和虛假宣傳活動也導致部分民眾猶豫不決，影響疫苗接種率。然而，新興市場蘊藏著巨大的機會和成長潛力，這些市場醫療支出不斷成長，公眾意識不斷提高，醫療基礎設施也不斷完善。製藥公司與國際衛生組織進行策略合作，制定價格合理的疫苗分發計劃，核准疫苗用於更廣泛的年齡群體，並持續進行潛在治療用途的臨床研究，這些都為市場擴張和改善全球健康狀況提供了可觀的途徑。

本次調查的主要特點

本報告對全球Gardasil市場進行了詳細分析，以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和復合年成長率（%）。
它還重點介紹了各個細分市場的潛在商機，並為該市場說明了一個有吸引力的投資提案矩陣。
該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要參與企業。
本報告基於以下幾個方面，對全球Gardasil市場的主要企業進行了分析：公司概況、產品系列、主要特徵、財務表現和策略。
本報告的研究結果將幫助負責人和經營團隊就即將推出的產品、類型升級、市場擴張和行銷策略做出明智的決策。
這份全球Gardasil市場報告的目標受眾是該行業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過全球Gardasil市場分析中使用的各種策略矩陣輕鬆做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第12章競爭格局

Merck & Co., Inc.

第13章分析師建議

機會
一致的機會地圖

第14章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI8975

Gardasil Market is estimated to be valued at USD 5.14 Bn in 2025 and is expected to reach USD 11.15 Bn by 2032, growing at a compound annual growth rate (CAGR) of 11.7% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 5.14 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	11.70%	2032 Value Projection:	USD 11.15 Bn

The global Gardasil market represents a critical segment within the preventive healthcare and vaccine industry, focusing on human papillomavirus (HPV) prevention through immunization. Gardasil, developed by Merck & Co., is a prophylactic vaccine designed to protect against specific strains of HPV that are primarily responsible for cervical cancer, genital warts, and other HPV-related malignancies. The vaccine has evolved from its original quadrivalent formulation (Gardasil 4) targeting HPV types 6, 11, 16, and 18, to the current nonavalent version (Gardasil 9) that provides protection against nine HPV strains, significantly expanding its preventive capabilities.

The market encompasses various stakeholders including pharmaceutical manufacturers, healthcare providers, government health agencies, and end-users across different age demographics. Global health organizations, including the World Health Organization and Centers for Disease Control and Prevention, have endorsed HPV vaccination as a crucial public health intervention, driving widespread adoption across developed and emerging markets. The market dynamics are influenced by factors such as increasing awareness of HPV-related diseases, expanding vaccination programs, regulatory approvals for broader age groups and gender inclusion, and growing healthcare infrastructure investments worldwide, positioning Gardasil as an essential component of comprehensive cancer prevention strategies.

Market Dynamics

The global Gardasil market is primarily driven by escalating awareness regarding HPV-related cancers and the critical role of preventive vaccination in reducing disease burden, particularly cervical cancer which represents the fourth most common cancer among women worldwide. Government initiatives and national immunization programs across developed countries have significantly accelerated market adoption, with many nations including HPV vaccination in their routine immunization schedules for adolescents. The expansion of target demographics beyond the initial female population to include males has substantially broadened the addressable market, as healthcare authorities recognize the importance of gender-neutral vaccination strategies in achieving herd immunity and reducing overall HPV transmission. Technological advancements in vaccine formulation, particularly the transition from quadrivalent to nonavalent Gardasil, have enhanced protection coverage and improved market positioning.

However, the market faces considerable restraints including high vaccine costs that limit accessibility in price-sensitive regions, cultural and religious barriers affecting vaccination acceptance, particularly in conservative societies where discussions about sexually transmitted infections remain taboo. Supply chain complexities and cold storage requirements pose additional challenges, especially in developing countries with inadequate healthcare infrastructure. Anti-vaccine sentiment and misinformation campaigns have also created hesitancy among certain population segments, impacting uptake rates. Nevertheless, substantial opportunities exist in emerging markets where increasing healthcare spending, growing awareness campaigns, and expanding healthcare infrastructure present significant growth potential. Strategic partnerships between pharmaceutical companies and international health organizations for affordable vaccine distribution programs, coupled with ongoing clinical research for expanded age group approvals and potential therapeutic applications, represent promising avenues for market expansion and improved global health outcomes.

Key Features of the Study

This report provides in-depth analysis of the global Gardasil market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Gardasil market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Merck & Co. Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global Gardasil market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Gardasil market

Market Segmentation

Vaccine Type Insights (Revenue, USD Bn, 2020 - 2032)
- Gardasil (Quadrivalent)
- Gardasil 9 (Nonavalent)
Disease Prevention Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Cervical Cancer Prevention
- Vulvar and Vaginal Cancer Prevention
- Anal Cancer Prevention
- Oropharyngeal Cancer Prevention
- Genital Warts Prevention
Dosage Schedule Insights (Revenue, USD Bn, 2020 - 2032)
- 2-Dose Schedule
- 3-Dose Schedule
Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adolescents (typically 9-14 years)
- Young adults (15-26 years)
- Adults (above 26 years)
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and Multispecialty Centers
- Pediatric and Gynecology Clinics
- Academic and Research Institutions
- Corporate, Workplace Vaccination Programs
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Public sector
- Private sector
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Merck & Co., Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Gardasil Market, By Vaccine Type
- Global Gardasil Market, By Disease Prevention Indication
- Global Gardasil Market, By Dosage Schedule
- Global Gardasil Market, By Gender
- Global Gardasil Market, By Age Group
- Global Gardasil Market, By End User
- Global Gardasil Market, By Distribution Channel
- Global Gardasil Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Gardasil Market, By Vaccine Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Gardasil (Quadrivalent)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Gardasil 9 (Nonavalent)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Gardasil Market, By Disease Prevention Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Cervical Cancer Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Vulvar and Vaginal Cancer Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Anal Cancer Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Oropharyngeal Cancer Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Genital Warts Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Gardasil Market, By Dosage Schedule, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
2-Dose Schedule
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
3-Dose Schedule
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Gardasil Market, By Gender, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Gardasil Market, By Age Group, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adolescents (typically 9-14 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Young adults (15-26 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Adults (above 26 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Gardasil Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals and Multispecialty Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Pediatric and Gynecology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Academic and Research Institutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Corporate, Workplace Vaccination Programs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Gardasil Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Public sector
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Private sector
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Gardasil Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Vaccine Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Prevention Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Schedule, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Vaccine Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Prevention Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Schedule, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Vaccine Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Prevention Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Schedule, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Vaccine Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Prevention Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Schedule, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Vaccine Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Prevention Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Schedule, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Vaccine Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Prevention Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Schedule, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa